Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Follow-On Biologics Theatre: Next Act Is FDA

This article was originally published in The Pink Sheet Daily

Executive Summary

A House subcommittee hearing on FTC’s report on FOB competition includes yelling, a “challenge” to take an FOB product – and a promise from Chairman Pallone for more of the same.

You may also be interested in...



FTC Biosimilars Workshop: Second Time’s The Charm?

Having failed to significantly influence the design of the federal approval pathway, the Commission is hoping to have an impact on product naming and state substitution laws.

Biosimilars Pathway: Lack Of Orange Book For Patents Worries Momenta

Avoiding the problems created by the small-molecule "Orange Book" patent catalog was one of the motivations for congressional drafters when they developed the biosimilars pathway, but the alternate patent challenge process the law created has left at least one generic firm wistful for fights over "delisting" and "ministerial" duties

Biosimilars Pathway: Lack Of Orange Book For Patents Worries Momenta

Avoiding the problems created by the small-molecule "Orange Book" patent catalog was one of the motivations for congressional drafters when they developed the biosimilars pathway, but the alternate patent challenge process the law created has left at least one generic firm wistful for fights over "delisting" and "ministerial" duties

Related Content

Topics

UsernamePublicRestriction

Register

LL1129949

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel